Considering that local therapy has a role in all patients with AD and, with the limitations of existing options, there is also a huge unmet need for new topical agents
“There is a lot of public phobia about topical corticosteroids, and the topical calcineurin inhibitors carry a black box warning,” Dr. Guttman-Yassky says.
The topical PDE-4 inhibitor crisaborole 2% ointment (Pfizer) showed promising results in trials and was approved for mild-to-moderate atopic dermatitis by the U.S. Food and Drug Administration in December, 2016. The approval was based on the positive results from the phase 3 trials. Crisaborole is approved for children and adults 2 years of age and older.
In a phase 2a vehicle-controlled trial, the topical JAK inhibitor tofacitinib (Pfizer) showed great results when used to treat adults with mild-to-moderate AD.
“In fact, the benefit of topical tofacitinib was much better for AD than for psoriasis,” Dr. Guttman-Yassky says.
“Most ongoing studies with JAK inhibitors involve systemic agents, but hopefully other topical JAK inhibitors will follow the promising study with topical tofacitinib because there is a great need for new topical treatments.”
Disclosures: Dr. Guttman-Yassky is a consultant to most companies that develop medications for AD, including the agents mentioned in this article, but she receives no financial gain from any product.